Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved entities : Takeda pharmaceutical company limited save search
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -0.42% -1.11% 480K
|
Manufacturing
| Email alert
Add to watchlist
ALPMF | News | $9.5 -2.56% 43.47% 1.2K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
| Email alert
Add to watchlist
granted approval cancer treatment for
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Published: 2024-04-18 (Crawled : 23:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
entyvio fda disease active for therapy
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Published: 2024-03-19 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: -0.96%
iclusig fda drug takeda approval application
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Published: 2024-02-12 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.46%
C: 0.42%
fda first treatment
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.78%
C: 0.78%
hyqvia approved therapy
Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies
Published: 2023-12-21 (Crawled : 00:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.29%
C: 0.0%
livtencity approval cytomegalovirus treatment china
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Published: 2023-11-17 (Crawled : 15:30) - prnewswire.com
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 1.75%
H: 0.32%
C: -0.07%
takhzyro label update group
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD
Published: 2023-10-18 (Crawled : 22:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -1.61%
H: 0.14%
C: -0.27%
cd30 adcetris treatment
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.38%
C: 0.25%
japan approval
Global Hemophilia Research Analysis Report 2023: A $21.07 Billion Market by 2030 - Approval of Gene Therapies and Monoclonal Antibodies Fueling Growth
Published: 2023-08-16 (Crawled : 01:00) - prnewswire.com
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.26%
H: 0.26%
C: -0.46%
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.71%
H: 1.45%
C: 0.97%
NVO | News | $128.64 2.7% -1.0% 3.5M
|
Health Technology
|
| O: -0.3%
H: 1.35%
C: 0.05%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
report approval research global growth market
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
Published: 2023-04-11 (Crawled : 13:20) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.36%
H: 0.35%
C: -0.12%
hyqvia fda children approval
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
Published: 2023-01-11 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 1.04%
H: 0.32%
C: 0.19%
exkivity approval therapy
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Published: 2022-12-08 (Crawled : 13:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
qdenga vaccine approved
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
Published: 2022-11-17 (Crawled : 14:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.22%
H: 1.46%
C: 1.38%
iclusig approved trial
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
Published: 2022-11-11 (Crawled : 11:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.87%
H: 0.95%
C: 0.95%
cytomegalovirus treatment disease one infection
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistan...
Published: 2022-11-11 (Crawled : 11:00) - biospace.com/
RLYB | News | $1.74 -1.7% 3.8% 220K
|
|
| O: -25.22%
H: 14.77%
C: 11.58%
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.87%
H: 0.95%
C: 0.95%
cytomegalovirus treatment disease infection
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
Published: 2022-10-14 (Crawled : 15:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.62%
H: 0.69%
C: -0.69%
candidate chmp vaccine dengue approval positive tak-003 qdengue
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
Published: 2022-08-22 (Crawled : 17:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -1.01%
H: 1.16%
C: 0.44%
qdenga vaccine approved qdengue
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL | $23.29 1.84% 1.82% 1.9M
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.